- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ARS Pharmaceuticals, Inc(SPRY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SPRY
11/20/2026: SPRY (1-star) is currently NOT-A-BUY. Pass it for now.
ARS Pharmaceuticals is a commercial-stage biopharmaceutical company best known for its flagship product, neffy, a pioneering needle-free intranasal epinephrine spray for treating severe allergic reactions. The company's primary business strength lies in its first-mover advantage and proprietary absorption technology, which offer a convenient alternative to traditional auto-injectors and are driving rapid revenue growth. Its core investment story centers on converting needle-phobic patients and capturing expanding market share globally. However, key risks include heavy product concentration, ongoing operating losses, and potential insurance reimbursement hurdles. The stock suits growth-oriented investors willing to tolerate biotech volatility while monitoring ongoing sales adoption and formulary coverage developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Rapid top-line revenue expansion and high market potential make it attractive for growth strategies. |
| Momentum investor | Mixed fit | Momentum fit is conditional on a positive price breakout and sustained upward technical momentum. |
| Value investor | Weak fit | The absence of current earnings or positive free cash flow makes it unsuited for traditional value metrics. |
| Dividend investor | Weak fit | The company pays no dividends and reinvests all capital into commercial growth. |
| Low-risk investor | Weak fit | High clinical, commercial, and price volatility characteristics conflict with low-risk objectives. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences significant price swings based on commercial milestones and market sentiment. |
| Valuation risk | Medium / high | Valuation relies heavily on long-term projections of neffy adoption rather than current earnings. |
| Competition risk (traditional auto-injectors) | Medium | Entrenched legacy device manufacturers pose ongoing market adoption hurdles. |
| Business quality | Medium | The company features a high-value proprietary product but lacks broad multi-product diversification. |
| Dividend income | Low / none | No cash distributions are provided to shareholders. |
| Execution risk | High | Success depends heavily on effective commercial scaling and securing favorable insurance coverage. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 297.56M USD | Price to earnings Ratio - | 1Y Target Price 17 |
Price to earnings Ratio - | 1Y Target Price 17 | ||
Volume (30-day avg) 2.2M shares | Beta 1.16 | 52 Weeks Range 2.44 - 13.15 | Updated Date 11/21/2026 |
52 Weeks Range 2.44 - 13.15 | Updated Date 11/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.01 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -19.2% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales - neffy (United States) | Direct commercial sales of neffy for the emergency treatment of Type I allergic reactions in the U.S. | This is the primary engine driving top-line revenue growth. |
| International Partnerships & Licensing | Milestone payments and royalties from commercialization partners distributing neffy (EURneffy) overseas. | Provides secondary capital streams and expands global reach without heavy direct operational spend. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 281.02M | Price to Sales(TTM) 2.44 |
Enterprise Value 281.02M | Price to Sales(TTM) 2.44 | ||
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA -9.88 | Shares Outstanding 100.53M | Shares Floating 49.12M |
Shares Outstanding 100.53M | Shares Floating 49.12M | ||
Percent Insiders 16.01 | Percent Institutions 89.1 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

